Prosecution Insights
Last updated: November 04, 2026
Application No. 18/959,494

TRILAYERED BIOMIMETIC HYDROGEL SCAFFOLDS OF DUAL MICROENVIRONMENT AND PREPARATION METHOD AND APPLICATION THEREOF

Non-Final OA §103§112
Filed
Nov 25, 2024
Priority
Dec 01, 2023 — CN 202311635480.4
Examiner
WOZNICKI, JACQUELINE
Art Unit
3774
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Xinxiang Medical College
OA Round
1 (Non-Final)
50%
Grant Probability
Moderate
1-2
OA Rounds
1y 8m
Est. Remaining
76%
With Interview

Examiner Intelligence

Grants 50% of resolved cases
50%
Career Allowance Rate
480 granted / 964 resolved
-20.2% vs TC avg
Strong +26% interview lift
Without
With
+26.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 7m
Avg Prosecution
83 currently pending
Career history
1082
Total Applications
across all art units

Statute-Specific Performance

§101
2.0%
-38.0% vs TC avg
§103
47.7%
+7.7% vs TC avg
§102
16.2%
-23.8% vs TC avg
§112
32.7%
-7.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 964 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Objections Claims 1-7 are objected to because of the following informalities: Claim 1 is objected to for claiming “a…scaffolds” which is grammatically incorrect. It is further unclear from this whether or not one or more than one scaffold are being claimed. The claim is further unclear for claiming it includes “a cartilage layer GL-HPKGN” when it is unclear if this “GL-HPKGN” is simply a nickname for the cartilage layer, or whether it is intended to impart some meaning to the layer. If it is simply a nickname, it should be included in parentheses and consistently referred to throughout the claims whenever the “cartilage layer” is being discussed. If this is intended to impart some meaning to the cartilage layer or represents some abbreviation for something else, it is unclear what meaning this might impart, since there is no explanation of the abbreviation/additional meaning in the claim. Similarly, the claim refers also to “an intermediate layer GL-GMA” and “a bone layer GL-HP/GMAT” without any explanation what the letters mean after the “intermediate layer” or “bone layer”. The claim is further objected to for claiming “…and a bone layer GL-HP/GMAT; By…”, and “…in GL-HPKGN; Based on…” but it is improper to capitalize the word “by” in the middle of a sentence. The claim is further objected to for defining hydroxyphenylpropionic acid (HPA)” multiple times. The claim is further unclear for referring to “GMA” in the claim when it has previously referred to GL-GMA, and GL-GMAAT and it is unclear how, if at all, these all relate to one another. The claim is further unclear for referring to “gelatin” multiple times, meaning there is improper antecedent basis for at least one recitation of gelatin. The claim is further unclear for referring to “bone-specific microenvironment” when it is unclear how, if at all, this relates to the previously claimed “dual microenvironment”. Claim 2 is objected to for claiming “the…scaffolds” when it is unclear if claim 1 is actually only referencing one scaffold or not. The claim is also objected to for claiming “a trilayered mimetic hydrogel scaffolds of dual microenvironment” since it is unclear what it means to be “of dual microenvironment”. It is unclear whether the scaffold is intended to be placed within a dual microenvironment, whether the scaffold has a dual microenvironment, whether this relates to a method of formation, or something else. It is unclear whether this is intended to impart some structural limitation to the claim. If it is intended to impart meaning thereto, it is unclear exactly what meaning it should impart, since this is not understood to have any fixed meaning in the art. The claim is further objected to for having improper antecedent basis for “the chondrogenic microenvironment-specific GL-HPKGN layer”. It is further unclear what “the chondrogenic microenvironment-specific” layer is and how it relate to the previously claimed “dual microenvironment” and “cartilage layer GL-HPKGN”. The claim is further unclear for claiming “gelatin GL” when it is unclear what GL means in the context of this claim, and since there is improper antecedent basis for “gelatin”. The claim is further objected to for defining hydroxyphenylpropionic acid (HPA)” and “kartogenin (KGN)” again when they have already been defined in claim 1. Claim 3 is objected to for claiming “the…scaffolds” when it is unclear if claim 1 is actually only referencing one scaffold or not. The claim is also objected to for claiming “a trilayered mimetic hydrogel scaffolds of dual microenvironment” since it is unclear what it means to be “of dual microenvironment”. It is unclear whether the scaffold is intended to be placed within a dual microenvironment, whether the scaffold has a dual microenvironment, whether this relates to a method of formation, or something else. It is unclear whether this is intended to impart some structural limitation to the claim. If it is intended to impart meaning thereto, it is unclear exactly what meaning it should impart, since this is not understood to have any fixed meaning in the art. The claim is further objected to for capitalizing “The” in the middle of a sentence. The claim is further unclear for referring to “[t]he gelatin-p-hydroxyphenylpropionic acid GL-HPAT” with improper antecedent basis. It is further unclear how this relates, if at all, to the previously claimed “cartilage layer GL-HPKGN”, “bone layer GL-HP/GMAT”, either one of the gelatins, or the cartilage-specific microenvironment in HPKGN. The claim is further objected to for referring to adding “p-hydroxyphenylpropionic acid (HPA)” when HPA has already been defined in previous claims, and since “p-hydroxyphenylpropionic acid” appears to be distinct from “hydroxyphenylpropionic acid” as HPA was previously defined as. The claim is further objected to for referring to “atorvastatin (AT)” and “dimethyl sulfoxide (DMSO)” when both of these claims have already been defined in claim 2. The claim is further objected to for having a period in the middle of the claim, and no space between the “GL.The”. The claim is further unclear for referring to “gelatin-p-hydroxyphenylpropionic acid GL-HPAT” with improper antecedent basis. Claim 4 is objected to for claiming “the…scaffolds” when it is unclear if claim 1 is actually only referencing one scaffold or not. The claim is also objected to for claiming “a trilayered mimetic hydrogel scaffolds of dual microenvironment” since it is unclear what it means to be “of dual microenvironment”. It is unclear whether the scaffold is intended to be placed within a dual microenvironment, whether the scaffold has a dual microenvironment, whether this relates to a method of formation, or something else. It is unclear whether this is intended to impart some structural limitation to the claim. If it is intended to impart meaning thereto, it is unclear exactly what meaning it should impart, since this is not understood to have any fixed meaning in the art. The claim is further objected to for referring to “the pH” with improper antecedent basis. The claim is further objected to “the gelatin-p-hydroxyphenyl acetic acid (GL-HPAAT) solution”. It is further unclear how this relates to the previously claimed gelatin-p-hydroxyphenylpropionic acid GL-HPAT, the gelatin(s), the HPA, and all the other materials. The claim is further objected to for referring to “HCl” when abbreviations or acronyms should have explanation before their use in the claim. Claim 5 is objected to for claiming “the…scaffolds” when it is unclear if claim 1 is actually only referencing one scaffold or not. The claim is also objected to for claiming “a trilayered mimetic hydrogel scaffolds of dual microenvironment” since it is unclear what it means to be “of dual microenvironment”. It is unclear whether the scaffold is intended to be placed within a dual microenvironment, whether the scaffold has a dual microenvironment, whether this relates to a method of formation, or something else. It is unclear whether this is intended to impart some structural limitation to the claim. If it is intended to impart meaning thereto, it is unclear exactly what meaning it should impart, since this is not understood to have any fixed meaning in the art. The claim is further unclear for referring to “gelatin” with improper antecedent basis. It is further unclear how “gelatin (GL)” relates to the previously mentioned gelatins, and previously mentioned materials with GL in their name. The claim is further unclear for referring to “methyl methacrylate (GMA)” when GMA has already been defined in claim 1. Claim 6 is objected to for claiming “the…scaffolds” when it is unclear if claim 1 is actually only referencing one scaffold or not. The claim is also objected to for claiming “a trilayered mimetic hydrogel scaffolds of dual microenvironment” since it is unclear what it means to be “of dual microenvironment”. It is unclear whether the scaffold is intended to be placed within a dual microenvironment, whether the scaffold has a dual microenvironment, whether this relates to a method of formation, or something else. It is unclear whether this is intended to impart some structural limitation to the claim. If it is intended to impart meaning thereto, it is unclear exactly what meaning it should impart, since this is not understood to have any fixed meaning in the art. The claim is further unclear for referring to “the cartilage layer (GL-HPKGN)” when the claim has previously referred to “the cartilage layer GL-HPKGN” and it is unclear how, if at all, these relate to one another. The claim is further unclear for referencing “a gel” when it is unclear how, if at all, this relates to the “hydrogel” of the scaffold previously referenced. The claim is further unclear for referring to “the enzymatic oxidation reaction” with improper antecedent basis. The claim is further unclear for referring to “H2O2” when abbreviations/acronyms should clearly reference the element being discussed in the claim before using the abbreviation. The claim is further objected to for missing a space between “…H2O2;the…”. The claim is further unclear for referring to “a gel” and “the enzymatic oxidation reaction” multiple times in the claim, indicating a lack of antecedent basis. The claim is further objected to for referring to “horseradish peroxidase (HRP)” multiple times, indicating a lack of antecedent basis. The claim is further objected to for missing a word after “light curing” (e.g. “and”). The claim is further unclear for referring to being “quickly” cross-linked but the specification fails to describe exactly what “quickly” means and so the Examiner cannot understand the boundaries and limitations of the claim. Claim 7 is objected to for claiming “the…scaffolds” when it is unclear if claim 1 is actually only referencing one scaffold or not. The claim is also objected to for claiming “a trilayered mimetic hydrogel scaffolds of dual microenvironment” since it is unclear what it means to be “of dual microenvironment”. It is unclear whether the scaffold is intended to be placed within a dual microenvironment, whether the scaffold has a dual microenvironment, whether this relates to a method of formation, or something else. It is unclear whether this is intended to impart some structural limitation to the claim. If it is intended to impart meaning thereto, it is unclear exactly what meaning it should impart, since this is not understood to have any fixed meaning in the art. The claim is further unclear for referring to “The application” with improper antecedent basis. The Examiner notes the claim from which this depends is a “scaffold(s)”, making this unclear. There is further improper antecedent basis for “the preparation”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-7 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. Claim 1 is indefinite for claiming “a trilayered mimetic hydrogel scaffolds of dual microenvironment” since it is unclear what it means to be “of dual microenvironment”. It is unclear whether the scaffold is intended to be placed within a dual microenvironment, whether the scaffold has a dual microenvironment, whether this relates to a method of formation, or something else. It is unclear whether this is intended to impart some structural limitation to the claim. If it is intended to impart meaning thereto, it is unclear exactly what meaning it should impart, since this is not understood to have any fixed meaning in the art. The specification does not define this in any special way, and it appears there could be many definitions that might apply to it. The claim further is unclear for claiming a photo-crosslinking reaction “was used” to graft AT onto gelatin, when it is unclear whether this is an attempt to claim a method of manufacture within the claimed structure of the scaffold(s), or whether this is simply describing how the dual crosslinking network was created without actually requiring this for the claim. The claim is further unclear for claiming the intermediate layer “was beneficial for forming a clear and defined cartilage-bone integrated structure”. First, it is unclear how something being beneficial relates to the claimed scaffold(s), and whether this imparts any structural or functional requirement thereto. Second, it is unclear what it means to be a “clear and defined” structure. The specification does not appear to elaborate on what it means to be a “clear and defined” structure, meaning the Examiner is unclear on what would fit within the boundaries of the “clear” or “defined” and what would not. Third, it is unclear how this “cartilage-bone integrated structure” relates to the “scaffold(s)”, cartilage layer, intermediate layer, or bone layer. As claimed it appears it is intended to be a completely different structural element of the scaffold, but based on the specification the Examiner is unsure. Claim 3 is indefinite for referring to “methylpropenylglycide (GMA)” when claim 1 has already defined “GMA”, but has defined it as “methacryloyl-glycidyl dimethicone”. The claim is further indefinite to for claiming the bone layer “was prepared” by mixing elements together when it is unclear whether or not this is attempting to positively claim the method of production of the bone layer, or whether this is simply commenting on how it was prepared. It is unclear what is required for the claim and what is not. Claim 5 is indefinite for referring to “methyl methacrylate (GMA)” when claim 1 has already defined “GMA” as “methacryloyl-glycidyl dimethicone”. Remaining claims are rejected for depending on a rejected claim. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-7 is/are rejected under 35 U.S.C. 103 as being unpatentable over Oezguerbuez (TR 201011221 A2) in view of Zhang et al. (CN 114984315 A) hereinafter known as Zhang, further in view of Wang et al. “Modulation of chondrocyte functions and stiffness-dependent cartilage repair using an injectable enzymatically crosslinked hydrogel with tunable mechanical properties”, Biomaterials, 35 (2014) 2207-2217, (hereinafter known as Wang), and further in view of Shah et al. “Novel applications of statins for bone regeneration”, Natl Sci Rev., 2015 March 1; 2(1): 85-99, hereinafter known as Shah, further in view of Lim et al. (WO 2017095240 A1) hereinafter known as Lim. Regarding claim 1 Oezguerbuez discloses a tri-layered (Figure 1 which shows layers 2, 3, 4) biomimetic scaffold (Figure 1) of dual microenvironment (Figure 1 shows at least two “environments” which are considered to have microstructure, 2 and 4) characterized in that it includes a cartilage layer (2; page 2 last line to page 3 line 1 of the translation), an intermediate layer (3; page 2 line 4), and a bone layer (4; page 2 lines 4-5); wherein gelatin forms a cartilage-specific microenvironment in the cartilage layer (page 4 paragraph 3, lines 1-3), wherein gelatin forms the bone layer with a bone-specific microenvironment (page 5, last paragraph, lines 1-3), wherein the intermediate layer forms a clear and defined cartilage-bone integrated structure (Figure 1 item 3 shows a clear and defined structure which is considered to be a cartilage-bone integrated structure since it sits between the cartilage layer 2 and bone layer 4), but is silent with regards to the scaffold being hydrogel, the cartilage layer being formed by an enzymatic crosslinking reaction and being based on hydroxyphenylpropionic acid (HPA), to have kartogenin (KGN) grafted onto gelatin, and the bone layer including a dual-crosslinking network which is formed by enzyme crosslinking reaction based on HPA, and methacryloyl-glycidyl dimethicone (GMA) photo-crosslinking reaction, to graft atorvastatin (AT) onto gelatin to form the bone layer. However, regarding claim 1 Zhang teaches a tissue engineering composition (Abstract: promotes cartilage ECM deposition and improves cartilage defect repair potential) can be made of a hydrogel (Abstract: dynamic protein hydrogel), that includes a layer for replacing cartilage (Abstract: cartilage defect repair potential) that can be formed by an [chemical] crosslinking reaction and being based on HPA, to have KGN grafted onto gelatin (Abstract: gelatin, Au3+, and KGN are crosslinked). Further, Wang teaches crosslinking of gelatin can occur via an enzymatic process using HPA (Abstract). Oezguerbuez, Zhang, and Wang are involved in the same field of endeavor, namely tissue engineering materials. It would have been obvious to one of ordinary skill in the art at the time the invention was filed to modify the scaffold of Oezguerbuez so that it is made of a hydrogel formed with KGN grafted onto gelatin as is taught by Zhang since KGN is known in the art to promote differentiation of mesenchymal stem cells into cartilage and thus relieves cartilage matrix degradation caused by inflammation. Further, it would have been obvious to crosslink via enzymatic means as opposed to chemical means, as is taught by Wang, since both chemical and enzymatic crosslinking mechanisms are found successful in the art, and the courts have held that the simple substitution of one known element for another to obtain predictable results in a prima facie case of obviousness. See MPEP 2143 (I)(B). Further, regarding claim 1 Shah teaches the use of gelatin (page 8 last paragraph: hydrogels are a popular method of local delivery for bone application, including gelatin) to deliver statins, including AT (page 1, introduction, third to last line), for use within bone regeneration (Abstract). Oezguerbuez and Shah are involved in the same field of endeavor, namely tissue engineering. It would have been obvious to one of ordinary skill in the art at the time the invention was filed to modify the scaffold of the Oezguerbuez Zhang Wang Combination so that the bone layer included AT as is taught by Shah in order to result in the bone layer of the Combination promoting bone generation, while minimizing inflammation and providing antimicrobial properties. Further, Wang already teaches that gelatin crosslinking can occur via enzymatic processes using HPA (see the rejection directly above where this is addressed), and Lim further teaches a gelatin hydrogel (page 1 lines 21-28), such as was created by the Oezguerbuez Zhang Wang Shah Combination, benefits from photo polymerization, and this crosslinking polymerization can occur via GMA (page 1 line 33-page 2 line 3). Oezguerbuez and Lim are involved in the same field of endeavor, namely tissue scaffolds. It would have been obvious to one of ordinary skill in the art at the time the invention was filed to modify the scaffold of the Oezguerbuez Zhang Wang Shah Combination so that its gelatin-AT bone layer is also crosslinked via GMA as is taught by Lim in order to allow control over the polymerization process, allowing it to be performed at room or physiological temperatures, with fast curing rates and minimal heat generation, thus widening the possibilities of crosslinking in-situ. Regarding claim 2 the Oezguerbuez Zhang Wang Shah Lim Combination teaches the scaffold of claim 1 substantially as is claimed, wherein the Combination further teaches the cartilage layer is obtained by adding gelatin to HPA, KGN, dimethyl sulfoxide (DMSO), ultrapure water, N-hydroxysuccinimide, and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (The applicant is advised that this is a product-by-process claim. Even though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process”. See MPEP 2113. In this case, the cited limitations failed to distinguish the claimed structure from the Combination, since all the structural limitations of the claim appear to be met.). Regarding claim 3 the Oezguerbuez Zhang Wang Shah Lim Combination teaches the scaffold of claim 2 substantially as is claimed, wherein the Combination further teaches the bone layer is obtained by mixing gelatin-p-hydroxyphenylpropionic acid and GMA, wherein the gelatin-p-hydroxyphenylpropionic acid is obtained by adding HPA, AT, DMSO, ultrapure water, N-hydroxysuccinimide, and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride to gelatin (The applicant is advised that this is a product-by-process claim. Even though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process”. See MPEP 2113. In this case, the cited limitations failed to distinguish the claimed structure from the Combination, since all the structural limitations of the claim appear to be met.). Regarding claim 4 the Oezguerbuez Zhang Wang Shah Lim Combination teaches the scaffold of claim 3 substantially as is claimed, wherein the Combination further teaches a pH of the gelatin-p-hydroxyphenylpropionic acid solution is adjusted to 4-5 using HCl (this appears to be drawn towards something other than a part of the claimed scaffold). Regarding claim 5 the Oezguerbuez Zhang Wang Shah Lim Combination teaches the scaffold of claim 1 substantially as is claimed, wherein Oezguerbuez further discloses the intermediate layer is gelatin (page 5 paragraph 4 lines 1-6), and wherein Lim further teaches a gelatin layer can obtained by mixing gelatin (page 1 lines 21-28) with GMA (page 1 line 33-page 2 line 3). It would have been obvious to one of ordinary skill in the art at the time the invention was filed to modify the intermediate layer of the Combination so that it is mixed with GMA as is taught by Lim in order to allow the layer to have a structural similarity to the native extracellular matrix, have low immunogenicity, retain native molecular epitopes important for cell signaling, and allow control over the spatial and temporal processes of polymerization. Regarding claim 6 the Oezguerbuez Zhang Wang Shah Lim Combination teaches the scaffold of claim 2 substantially as is claimed, wherein Zhang further teaches a gelatin material (e.g. the gelatin of the cartilage layer, intermediate layer, or bone layer) is (quickly) crosslinked into a gel (Abstract), and wherein Wang further teaches the enzymatic oxidation reduction reaction between gelatin and GMA occurs with horseradish peroxidase (HRP) and hydrogen peroxide (Abstract) and is then subjected to light curing (or light exposure) (page 2208, last 5 lines of the second paragraph which indicates gelatin-GMA hydrogels are known to have UV exposure after preparation), Regarding claim 7 the Oezguerbuez Zhang Wang Shah Lim Combination teaches the scaffold of claim 1 substantially as is claimed, wherein Oezguerbuez further discloses the scaffold is capable of use in cartilage-bone tissue regeneration materials (Abstract, see also page 11, last paragraph before the claims). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jacqueline Woznicki whose telephone number is (571)270-5603. The examiner can normally be reached M-Th 10am-6pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jerrah Edwards can be reached on 408-918-7557. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Jacqueline Woznicki/Primary Examiner, Art Unit 3774
Read full office action

Prosecution Timeline

Nov 25, 2024
Application Filed
Sep 17, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766014
PROSTHETIC DEVICE
2y 9m to grant Granted Oct 20, 2026
Patent 12746172
POWERED ORTHOSIS WITH COMBINED MOTOR AND GEAR TECHNOLOGY
6y 10m to grant Granted Sep 29, 2026
Patent 12741062
ADDITIVE MANUFACTURE OF COMPLEX IMPLANTABLE LIVING DEVICES
3y 11m to grant Granted Sep 22, 2026
Patent 12734049
SYSTEMS AND METHODS FOR REINFORCEMENT LEARNING CONTROL OF A POWERED PROSTHESIS
4y 2m to grant Granted Sep 15, 2026
Patent 12721730
METHOD FOR DESIGNING A JOINT PROSTHESIS
4y 8m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
50%
Grant Probability
76%
With Interview (+26.4%)
3y 7m (~1y 8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 964 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month